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Abstract 
 
Much cross-cultural research has been done on the topic of schizophrenia, but few studies thus 
far have focused on lifetime prevalence and prognosis together, grouped by world region. 
Additionally, there has been severe bias in which countries and regions have been studied both 
historically and currently. Any study that had statistics on lifetime prevalence per 1000 people 
and/or DALYs, from a specified country or region, was included in this thesis. Results showed 
that lifetime prevalence of schizophrenia does not differ among WHO regions, but DALYs 
and thus prognosis do differ. Several major conclusions can be drawn from these results. One 
is that prognosis differs even though prevalence does not. Another is that schizophrenia is not 
a region-specific disorder. A third is that the reason that prevalence does not differ among 
regions could be due to biological causes of schizophrenia being more powerful than 
environmental causes. A fourth is that the reasons that prognosis differs in different regions 
are plentiful, but can all be derived from social support and community. The implications of 
these conclusions can be used to better the prognosis of people with schizophrenia worldwide, 
but further cross-cultural research in underrepresented countries is essential. 
Keywords: schizophrenia, lifetime prevalence, prognosis, cross-cultural 
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Do the Lifetime Prevalence and Prognosis of Schizophrenia Differ Among World Regions? 
 
1. Introduction 
 
Schizophrenia is a mental illness which has been widely researched by psychologists. 
Though the concept of schizophrenia, and the disorder itself, existed before 1911, this is when 
Eugen Bleuler first introduced the term in Europe. In Dementia Praecox, or the Group of 
Schizophrenias (1952), Bleuler explained that the previous name of dementia praecox (coined 
by Emil Kraepelin) implied too much of a link to dementia, and thus the new and separate 
name of schizophrenia would be more appropriate. Schizophrenia comes from the Greek “split 
mind,” which references a person with schizophrenia’s split between emotion and thought, 
and their general dissociations from reality. Because of this, schizophrenia is currently often 
confused with dissociative identity disorder (DID), which is actually a split of personality. 
Schizophrenia has been included in all five versions of the Diagnostic and Statistical Manual 
(DSM), however its name and definition have evolved with time. For example, the original 
DSM called it ‘schizophrenic reaction’ (APA, 1952). Currently, the DSM-5 states that 
schizophrenia is “defined by abnormalities in one or more of the five following domains: 
delusions, hallucinations, disorganised thinking (speech), grossly disorganised or abnormal 
motor behaviour (including catatonia), and negative symptoms” (APA, 2013, p. 87). These 
symptoms can be categorised as positive (i.e. the presence of delusions, hallucinations, and 
disorganised speech) or negative (i.e. social withdrawal, catatonia, and apathy). Symptoms 
must persist for at least six months for a diagnosis to be made. The onset of schizophrenia 
 
     
 LIFETIME PREVALENCE AND PROGNOSIS OF SCHIZOPHRENIA                    4 
usually occurs in the teenage years or early to mid-twenties, with cases of childhood 
schizophrenia being exceedingly rare.  
Schizophrenia is a particularly difficult disorder to diagnose. First, the DSM-5 
instructs psychologists and psychiatrists to consider other, potentially less severe disorders, 
and then to consider other disorders that may produce psychosis. A diagnosis of schizophrenia 
seems to be the last resort. In addition, some symptoms such as disorganised speech, 
delusions, and hallucinations may be difficult to evaluate completely due to linguistic 
differences between countries and cultures. Furthermore, the lack of a physical basis for the 
disorder may mean that diagnosis is potentially more arbitrary than disorders with a clear 
physical cause. The definition of schizophrenia and its diagnostic criteria has come far in the 
past few decades, but more data on the disorder are needed. 
While there is no one proven cause for schizophrenia so far, there has been research 
into many different biological, psychological, and environmental causes. Biological causes 
include genetic links (Nicodemus et al., 2008; Lewis et al., 2003; Badner & Gershon, 2002), 
viral infections such as influenza during pregnancy (Watson, Mednick, Huttunen, & Wang, 
1999), and biological sex, as the disorder is slightly more common in males. Psychological 
causes include comorbidity between schizophrenia and drug abuse disorders (Volkow, 2009). 
Environmental causes include low birth weight, hypoxia during birth (Nicodemus et al., 
2008), migration across countries in a person’s or their ancestor’s life (Cantor-Graae & Selten, 
2005), and stress. There are many gaps in this research, particularly cross-culturally, and thus 
more research should be done to determine the causes of schizophrenia in order to treat it 
more effectively. 
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The first hypothesis of this thesis is that the lifetime prevalence of schizophrenia will 
not be significantly different among WHO regions. Much of the research already done 
suggests that in general, lifetime prevalence does not significantly differ among regions. In 
addition, there has so far been no clear reason as to what would be causing differing lifetime 
prevalence rates among WHO regions. The second hypothesis is that the prognosis of 
schizophrenia will be significantly different among WHO regions. The background literature 
has suggested that cultures with less stigma against mental health issues, cultures with more 
social support, and developing countries generally have a better prognosis than cultures with 
more stigma against mental health issues, cultures with less social support, and developed 
countries. Therefore, I predict that the African Region, South-East Asia Region, and Eastern 
Mediterranean Region will generally have a better prognosis than the Region of the Americas, 
European Region, and Western Pacific Region. 
 
2. Background Information 
 
2.1 Historical Background of Schizophrenia 
The background literature will be categorised into six world regions: African Region, 
Region of the Americas, South-East Asia Region, European Region, Eastern-Mediterranean 
Region, and Western Pacific Region. These regions were pre-determined by the World Health 
Organisation (WHO), grouped together for geographical and perhaps cultural proximity. The 
WHO regions being used here are broad and therefore contain many different and unique 
cultures within them, and I will respectfully acknowledge this. In addition, it is understood and 
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recognised that within regions ethnicities and races will be diverse, but since these are much 
harder to track populations will be categorised by region.  
Much of the research thus far on schizophrenia in different regions has been Western-
centric. Arguably this Western bias in the research has potentially been detrimental to 
progressing our knowledge of schizophrenia. Even within these Western regions, there has 
been bias in the literature. Biases are not alone perpetrated by Western cultures, and this an 
also be seen in past research. This section of the literature review showcases the history of 
schizophrenia, and point out areas where there have been racial and/or cultural biases. These 
biases tend to manifest in stigma, lack of research, and unsuccessful treatment regimens. 
Research on schizophrenia in specific parts of the European Region is plentiful, especially 
surrounding minority communities and treatment regimens. A 1991 Census found that 
clinicians in the UK tend to over-diagnose the African-Caribbean community with 
schizophrenia, which demonstrates bias and that diagnosis of schizophrenia can often be 
arbitrary (Sharpley, Hutchinson, Murray, & McKenzie, 2001). People in this minority 
community diagnosed with schizophrenia were much more likely to be imprisoned. Historical 
treatments of schizophrenia in Europe have largely been ineffective, but persisted regardless 
because there was no alternative. For example, insulin coma therapy (ICT) and 
electroconvulsive therapy (ECT) were commonly used in the mid-20th Century (Jones, 2000). 
Lobotomies were also used as a treatment during this time, but this tended to cause a 
significant loss of higher functioning in people and is thus no longer used (Fields, 2010). 
Another European study examined the incidence of schizophrenia in ethnic minorities in 
London and found that minorities have a higher overall incidence of schizophrenia despite 
making up a smaller proportion of the population. This was especially true in areas where 
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minorities were less densely populated, suggesting that the increase in incidence stems from 
more stressful life events and less community to act as a support system (Boydell et al, 2001). 
Much of the research above took place in Western Europe, and there are a lot of gaps in 
research in Eastern Europe and non-English speaking European countries. Future research 
should focus on these underrepresented areas, and in discovering what treatment regimens 
would be more successful for people with schizophrenia. 
Much research has been conducted in the Region of the Americas. In the USA, 
schizophrenia is and was often pointed to as a cause of gun violence. This perpetuates the idea 
that all people with mental illnesses are generally violent and unstable, when in fact only 3-5% 
of violent crimes are committed by people with mental illnesses. In fact, they are more likely 
to be victims of gun violence than perpetrators. It was also found that only 5% of gun-related 
killings between 2001 and 2010 were committed by people with mental disorders (Metzl, 
2016). Metzl finds that over time, people diagnosed with schizophrenia are likely to become 
less violent, which could be attributed to the fact that the disorder is characterised by social 
isolation. In addition, during the American Civil Rights Movement of the 1960s, a diagnosis 
of schizophrenia was used as a weapon to dehumanise African-American citizens. African-
American men were significantly over-diagnosed with schizophrenia during this period, and 
similar to the trend in the UK those people diagnosed with schizophrenia were much more 
likely to be imprisoned. The effects of the stigmatization of schizophrenia as a violent disorder 
still last today (Metzl, 2010). African-Americans diagnosed with schizophrenia in the US are 
three times more likely to be prescribed antipsychotic medications than their white 
counterparts who display similar symptoms (Banerjee, 2012). These findings display a clear 
bias in diagnosis of schizophrenia, and unsuccessful and biased treatment regiments. Further 
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research in this area should focus on underrepresented communities in North America, and 
improving treatments for schizophrenia.  
The Region of the Americas is large, and also included Central and South America, 
and the Caribbean. In general, Latin American countries use less than 2% of their health 
budget for mental health resources, largely because of the cultural stigmatization of mental 
illness (Alarcón 2003). Those with schizophrenia in Latin American countries face 
homelessness, financial troubles, job loss, and general stigma from the community. The 
Caracas Declaration of 1990 aimed to reduce stigma and re-evaluate general approaches of 
mental illness. It was adopted by the majority of Latin American countries, but thus far, only 
Mexico is actively working towards making progress and change to the current system for an 
unknown reason. While there has been general research on mental illnesses in Central and 
South America, specific research on schizophrenia is lacking, potentially due to an internal 
bias and stigmatisation. Future research should focus on understanding why there is a 
significant stigma against mental health, how to combat this, and potential treatments. 
The countries of the African Region are often left out of both historical and contemporary 
studies of schizophrenia, even when the research is specifically focused on cross-cultural 
differences and similarities, for unknown reasons. The data that do exist are concentrated on 
specific countries and ignore others. Prior to the introduction of ‘mental asylums’ by the 
British in 1912, those with schizophrenia in many countries in Africa were treated by 
traditional healers (Odejide, Oyewunmi, & Ohaeri 1989). This generally involved the use of 
herbal medicines, praying to gods, and the use of shrines. After 1912, some people with 
schizophrenia were transferred to asylums built by the British in Africa, some were transferred 
to asylums in France, and few others remained in the care of their family and community. 
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New treatments for schizophrenia that originated in Europe and North America, like the 
previously mentioned ECT and ICT, reached regions in Africa very belatedly (Akyeampong, 
Hill, & Kleinman, 2015). Currently, many regions of Africa are undergoing rapid urbanisation 
and development, but mental health resources still remain scarce. Community health workers 
are vital sources of care for those without access to mental health professionals (Burns, 2012). 
It is important to remember that while this research does give us some context for the history 
of schizophrenia in Africa, firsthand accounts of African voices - those with schizophrenia and 
family or community members - go largely unheard in favour of the researcher’s voice. There 
are some countries in Africa in which a fair amount of research has been conducted, and then 
some countries in which there is no research. Future research should concentrate on 
representing regions of Africa which have not yet been researched, and improving treatment 
plans. 
Literature on the history of schizophrenia was also scarce in the Eastern 
Mediterranean Region. Research has found documentation of psychotic symptoms and other 
symptoms similar to schizophrenia in the ancient Egyptian Book of Hearts, written sometime 
before 2000 BC. These symptoms were thought to be caused by spirits, or poison in the heart 
or uterus (Korn, n.d.). More recently, one study found that the a well-educated population in 
Pakistan attributed the cause of schizophrenia to God’s will, superstitious ideas, loneliness, 
and unemployment rather than mental illness (Zafar et al., 2008). In 2016, the government of 
Pakistan ruled that schizophrenia is not a permanent condition and instead varies over time in 
the same person, and thus schizophrenia is curable and should not legally be considered a 
mental illness. This ruling was largely so the government could incarcerate a single individual 
with schizophrenia who had committed a crime (Dearden, 2016). Research is lacking in other 
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countries of the Eastern Mediterranean Region, which is where future research should focus. 
Specifically, research should focus on current and historical treatments of schizophrenia and 
potential stigma of governmental agencies against mental health issues there. 
Little research could be found on the history of schizophrenia in the South-East Asia 
Region of the world, which is also the WHO region with the least number of countries. Prior 
to the arrival of the British, those people with mental illnesses were usually cared for by their 
families and the general community. In the 19th Century, the British brought western 
approaches to mental health to India. After the 1857 Indian Rebellion Britain enforced the 
Lunacy Act of 1858 for most of the 19th Century, in which only Western approaches to 
medicine were used in asylums and traditional Indian approaches were not used. In the 1930s, 
ECT and ICT gained popularity as treatments for schizophrenia, like in many places in Europe 
and Africa. In the 1920s, people in asylums began to be referred to as ‘patients’ rather than 
‘lunatics’ in an effort to change the environment and attitude in mental asylums, but, “as late 
as 1945, the Assam Mental Hospital in Tezpur [was] described as in 'a mixed state of a prison, 
an asylum and a mental home'.” (“Medical History of British India”, 2007). In Thailand one 
study found that of 4,000 people in mental hospitals, 76% of them were diagnosed with 
schizophrenia. However, the actual prevalence of people with any mental illness in the 
population studied was very low (Ratanakorn, 1959). Most of the symptoms displayed were 
negative. Even though there was some research in India and Thailand, there was very little in 
other countries in the South-East Asia Region. The research that was conducted was only done 
after the arrival of the British, which introduces some bias. More general research on 
schizophrenia in the South-East Asia Region should be done as there is a lack of data thus far. 
Specifically, research on current treatments would be useful. 
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Research on the history of schizophrenia in the general Western Pacific Region 
yielded many results for Japan, but few results for other countries in the region. Prior to the 
1800s in Japan, it was believed that most mental illnesses were caused by spirits (Nakamura, 
2013). One treatment for this was hydrotherapy, which involves sitting under waterfalls, 
drinking clean water, etc. The same study found that from the 1800s to the 1950s, the main 
treatment for schizophrenia was home confinement. In 1900 the Law for the Confinement and 
Protection of the Mentally Ill was passed, essentially making the process of home confinement 
official - so much so that prison cells were being physically constructed in family homes for 
people living with schizophrenia. In 1940 a eugenics law was passed that allowed the 
sterilization of people with heritable mental illnesses, which included schizophrenia. In the 
1950s, similar to many other parts of the world mentioned so far, institutions began to gain 
popularity as the main treatment. Then in the 1980s, more attention was placed on patient’s 
rights due to requests from families of those will mental illnesses, and so hospitalisation 
became a popular treatment as it had better conditions than institutions. Several scandals in the 
1970s and 1980s that exposed conditions of these institutions led to mass 
deinstitutionalisation. In 2003 families of people with schizophrenia requested that the name 
be changed from seishinbunretsubyō (translated as ‘mind-split disease’) to tōgō shitchō-shō 
(translated as ‘integration disorder’) in order to reduce stigma and confusion about what the 
disorder actually is. This official change has made psychiatrists more comfortable being 
honest with their patients about being diagnosed with schizophrenia (Sato, 2006). In China 
one study found that people with schizophrenia rarely receive consistent treatment. The main 
form of treatment is solely medication (Phillips, 2001). This research shows that Japan is 
making progress with how their system deals with schizophrenia, and China could benefit 
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from more research on treatment for the disorder. There is a clear bias here in terms of which 
countries from the Western Pacific Region have been studied, and these findings should be 
used to fill gaps in the literature. 
To summarise the different cultural literature on schizophrenia that currently exists, it 
can be seen that much of the data is either biased (due to cultural stigmatisation of mental 
illnesses, or Western influences in research) or non-existent. It is important to remember that 
while Psychology itself is an old field, the term schizophrenia is fairly new in history. It may 
be that many countries have not studied or not been studied because they did not have the 
resources to fund and conduct in-depth research. This is not to say that none of the data we 
have thus far is not valuable, on the contrary: much of this data could provide context for the 
main portion of this thesis, which examines the similarities and differences of lifetime 
prevalence and general prognosis between WHO regions. 
  
2.2 Lifetime Prevalence of Schizophrenia 
Many studies have attempted to analyse the prevalence of schizophrenia globally. 
The total estimated number of people worldwide living with schizophrenia is 29 million, 
which is roughly 0.004% of the population. Research suggests that the incidence of 
schizophrenia (the proportion of new cases per year) remains relatively constant worldwide at 
0.1-0.4% (Barbato, 1996). I will focus on the prevalence of schizophrenia, since this has been 
much more widely researched. Schizophrenia is generally measured in three types of 
prevalence: point prevalence (the number of cases at one point in time), period prevalence (the 
number of cases over a specific period of time), and lifetime prevalence (the proportion of 
individuals who have been affected by schizophrenia at any time in their lives). Due to an 
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abundance of data, I will focus on lifetime prevalence only, which is measured per 1000 
people. Most studies thus far have examined the lifetime prevalence of schizophrenia on a 
global scale, and very little have examined the lifetime prevalence of schizophrenia in specific 
countries or regions. Some research suggests that prevalence does differ across regions, and 
few other studies find prevalence to be relatively constant worldwide (Jablensky, 2000).  
A full summary of the lifetime prevalence statistics found is located in the 
Appendices section of this thesis (Table 1). 
 
2.3 Prognosis in People with Schizophrenia 
WHO created a measurement to quantify the impact of a disease, and the general 
burden it has on society (burden of disease). A Disability-Adjusted Life Year (DALY) can be 
thought of as, “one lost year of ‘healthy’ life. The sum of these DALYs across the population, 
or the burden of disease, can be thought of as a measurement of the gap between current 
health status and an ideal health situation where the entire population lives to an advanced age, 
free of disease and disability” (“Metrics: Disability-Adjusted Life Year (DALY)”, n.d.). More 
information on how DALYs lost are calculated for particular diseases can be found in the 
above referenced website. DALYs lost can be thought of as one way to quantify the general 
prognosis of people with schizophrenia, and the social cost of schizophrenia to society. 
In 2004, WHO conducted a worldwide study in which they measured DALYs lost 
caused by schizophrenia for every country. In 1990, total DALYs lost worldwide due to 
schizophrenia was calculated to be just under 13 million, which puts schizophrenia at number 
26 for highest DALYs lost on a list of diseases. WHO has predicted that by 2020, around 17 
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million DALYs lost will be caused by schizophrenia, moving it up to the 20th position in the 
list (“Age-Standardised DALYs per 100,000 by Cause, and Member State, 2004”, 2004). 
Prognosis for people with schizophrenia is both historically and currently poor. 
Approximately 1 in 10 individuals with schizophrenia succeed in committing suicide. As 
previously shown, treatment regimens among regions have not improved much in the past 
century, which is one explanation for why prognosis is generally poor. In general, 30 years 
after being diagnosed with schizophrenia, 25% of people are completely recovered, 35% of 
people have improved and live mostly independently, 15% of people have improved but are 
not mostly independent, 10% of people are in hospitals or institutions, and 15% of people are 
dead - the most common cause of death being suicide (Torrey, 1988).  
There has been substantial research into what factors cause differing prognosis in 
people with schizophrenia. General factors which relate to prognosis can be found in 
Appendices (Appendix B). I will focus particularly on factors that relate to cross-cultural 
issues, such as: cultural stigma against mental illness, length of time a person spends without 
diagnosis and treatment, cultural differences in support, and economic development of a 
country. 
Cultural stigma against mental illness is prevalent to some extent in all cultures, but 
some countries have more systemic stigma than others. For example, a recent study found that 
due to stigma in many Latin American countries, they spend less than 2% of their health 
budget on mental health issues, effectively creating a systemic barrier to better prognosis in 
people with a wide range of mental illnesses (Alarcón, 2003). A second study recently 
conducted in Latin America found that the stigma of mental illness is very prevalent, leading 
to poorer prognoses than countries with less stigma against mental illnesses (Mascayano et al., 
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2016). A study conducted in several countries of Africa found that less stigma of 
schizophrenia leads to better prognosis. This stigma can be lessened by people with 
schizophrenia and their support systems (e.g. friends, family, community care workers, etc.) 
viewing it in a different perspective: as a short-term disorder with a high chance of recovery 
(Akyeampong, Hill, & Kleinman, 2015). Stigma is heavily rooted in culture and therefore 
could have a significant impact on the prognosis of people with schizophrenia living within 
that culture. 
The length of time between developing symptoms of schizophrenia and being 
diagnosed (and subsequently seeking treatment) also has an effect on the prognosis of people 
with schizophrenia. One study found that generally, the longer a period of time that a person 
spends undiagnosed, the worse the prognosis is for that person (Banerjee, 2012). Another 
study, conducted in Singapore, discovered that long periods of undiagnosed and untreated 
schizophrenia lead to worse prognosis. Therefore, clinicians and non-clinicians alike would 
greatly help combat this by using more effective ways to detect the early signs of 
schizophrenia (Kua, 2012). Leaving people undiagnosed and untreated for extended periods of 
time is detrimental to their prognosis, and this could depend on how much of a support system 
that person has, how much education the country has on mental health issues, and also stigma 
of seeking mental health support and treatments. 
Cultural differences in support is a third factor which ties in with cross-cultural issues 
in schizophrenia. One cross-cultural study found that people with schizophrenia in collectivist 
cultures (e.g. general African and Asian cultures) have fewer relapses and a milder course of 
illness than people with schizophrenia in individualistic cultures (e.g. general European and 
North American cultures). The study was unsure exactly why this is, but it could be due to the 
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fact that collectivist cultures tend to be higher in social support than individualistic cultures 
(MacDonald & Schulz, 2009). Continuing with this argument, another study found that social 
support and community are more important factors in prognosis than the type and severity of 
the symptoms presented (Elsheshtawy & Elez, 2011). A third study found that all people with 
schizophrenia who had good prognoses were living with their families, who provided social 
and emotional support (Kua, 2012). Clearly, the amount of social support provided is a 
significant factor in the prognosis of people with schizophrenia. This in turn is dependent on 
history and culture. 
A fourth factor that influences the prognosis of schizophrenia is whether the country 
is a developed or developing country. Examples of countries that fall into the ‘developed’ 
category are: USA, Canada, Japan, most European countries, and Australia. Examples of 
countries that fall into the ‘developing’ category are: Mexico, China, Indonesia, Jordan, and 
Thailand. One study found that in general, developing countries tend to have a better recovery 
rate than developed countries, with 40% of people with schizophrenia recovering in 
developing countries to 25% of people recovering in developed countries (Torrey, 1988). A 
second study also supported the hypothesis that prognosis is better in developing countries 
(Bhugra, 2005). The main difference between these developed and developing countries is an 
economic one. Thus, the development level of a country in terms of economic growth 
influences general prognosis in that country. 
Further factors which have been shown to influence prognosis, but are not 
particularly tied to cultural differences, can be found in the Appendices section (Table 2). 
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So far, we have seen that regions do tend to differ in terms of factors that influence 
prognosis of people with schizophrenia. I will use DALYs lost as a way to measure prognosis 
among different WHO regions. 
 
3. Methods 
  
 Lifetime prevalence data were gathered from previous studies. Some data were gathered by 
coincidence when searching for historical information. Other data was found using the search 
term “lifetime prevalence of schizophrenia in [country name]” in the Google Scholar database. 
WHO lists 195 countries and these were the country names searched. Then, in the interest of 
thoroughness, the search term “lifetime prevalence of schizophrenia in [WHO region]” was 
used to uncover any additional statistics. Due to an abundance of data and multiple different 
prevalence types, only lifetime prevalence was included. If provided, age-adjusted data was 
used instead of non-adjusted data. Lifetime prevalence per 1000 people only was included. 
Effort was made to include the most recent accurate lifetime prevalence data, though some 
data dates back several decades. Data was not included if it did not specify the prevalence 
type, since this could cause errors, or if it did not specify the region from which the data came, 
as this could not be classified correctly. Statistics were categorised by WHO region. Means 
and confidence intervals (CIs) were calculated for each region. The data were used to run a 
one-way ANOVA statistical test. Additionally, Levene’s p was calculated to make sure that 
homogeneity of variances could be assumed, since each WHO region had a very different 
sample size (p <0.05). No data could be found for lifetime prevalence of schizophrenia in any 
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Eastern Mediterranean country, or even just the region in general, and therefore it was 
discounted from this analysis.  
Prognosis was quantified by using DALYs lost, which had already been calculated by 
WHO for each country, but not manipulated to show regional differences. While manipulating 
the WHO data, it was found that the names of some countries had been updated since the 
study took place. This thesis uses the most recent official country names. Also, the Republic 
of South Sudan (which became independent from Sudan in 2011) did not exist when the 
original WHO study took place, and therefore has the same DALYs lost statistic as Sudan. All 
DALYs lost statistics were first categorised by WHO region. Then means and CIs were 
calculated. Additionally, Levene’s p was calculated to see if homogeneity of variances could 
be assumed, since the DALYs lost data had a rectangular distribution, but p > 0.05. No data 
transformations were successful in making the distribution normal. The data were used to run 
a Kruskal-Wallis nonparametric statistical test. Then, nonparametric post-hoc tests were run in 
order to determine differences between specific WHO regions. 
 
4. Results 
 
A summary image of the mean lifetime prevalence per 1000 people and mean 
DALYs lost per WHO region can be found below. Additionally, this image contains the 
number of countries in each WHO region. It also shows the number of lifetime prevalence 
statistics found (and % of countries sampled), and number of DALY statistics (and % of 
countries sampled) found by the researcher of this study.  
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Figure 1. The median lifetime prevalence, median DALYs lost, number of countries, number 
of lifetime prevalence stats found (% of countries sampled), and number of DALY stats (% of 
countries sampled) found per WHO region. 
 
The results of the ANOVA show that there is no statistically significant difference of 
lifetime prevalence statistics among WHO regions (F = 1.40, df = 4, 74, p = 0.24; Figure 2). 
For each WHO region included, the lifetime prevalence and 95% CIs were calculated: African 
Region ± 6.35 [3.15 to 9.55], Region of the Americas ± 1.27 [0.70 to 1.84], South-East Asia 
Region ± 4.06 [0.55 to 7.55], European Region ± 2.98 [2.01 to 3.95], and Western Pacific 
Region ± 3.10 [1.90 to 4.3]. 
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Figure 2. A boxplot showing the median lifetime prevalence per 1000 people, interquartile 
range, and points beyond these among WHO regions; N referring to the number of lifetime 
prevalence statistics found per WHO region (African  n=2, Americas n=9,  European n=27, 
South-East Asia n=4, Western Pacific n=37). 
 
The results of the Kruskal-Wallis test show that the difference among DALYs lost in 
WHO regions was statistically significant (X2(6)= 108.58, df = 5, p < 0.001; Figure 3). 
Additionally, post-hoc tests were conducted to determine which WHO regions were 
significantly different from each other, with a Bonferroni correction included (Table 1; Figure 
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4). For each WHO region, the mean DALY and 95% CIs were calculated: African Region ± 
241.16 [239.76 to 242.56], Region of the Americas ± 250.33 [244.83 to 255.83], South-East 
Asia Region ± 280.27 [266.27 to 294.27], European Region ± 211.55 [203.15 to 219.95], 
Eastern Mediterranean Region ± 266.18 [260.22 to 272.02], and Western Pacific Region ± 
271.49 [258.49 to 284.49].  
 
 
 
Figure 3. A boxplot showing the median Disability-Adjusted Life Years (DALYs) lost, 
interquartile range, and points beyond these among WHO regions; N showing the number of 
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DALYs lost statistics found per WHO region (African n=47, Americas n=35, Eastern 
Mediterranean n=22, European n=53, South-East Asia n=12, Western Pacific n=28). 
 
Table 1. Results of the post-hoc tests, showing whether the observed difference between 
WHO region medians is statistically significant or not, and the direction of this difference. 
WHO Region 1 WHO Region 2 Significantly 
Different? 
WHO Region with 
Higher Median 
African Americas No Americas 
 South-East Asia Yes South-East Asia 
 European No African 
 Eastern 
Mediterranean 
Yes Eastern Mediterranean 
 Western Pacific Yes Western Pacific 
Americas South-East Asia No South-East Asia 
 European Yes Americas 
 Eastern 
Mediterranean 
No Eastern Mediterranean 
 Western Pacific No Western Pacific 
South-East Asia European Yes South-East Asia 
 Eastern 
Mediterranean 
No Eastern Mediterranean 
 Western Pacific No Western Pacific 
European Eastern 
Mediterranean 
Yes Eastern Mediterranean 
 Western Pacific Yes Western Pacific 
Eastern 
Mediterranean 
Western Pacific No Western Pacific 
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Region 1 
Region 2 
African Americas South-East 
Asia 
European Eastern 
Mediterranean 
Western 
Pacific 
African N N Y (2) N Y (2) Y (2) 
Americas  N N Y (1) N N 
South-East Asia   N Y (1) N N 
European    N Y (2) Y (2) 
Eastern 
Mediterranean 
    N N 
Western Pacific      N 
 
Figure 4. A matrix showing significantly significant differences between two WHO regions in 
terms of DALYs lost (indicated by Y for a difference or N for no difference), and the direction 
of this difference (a (1) indicates that WHO region 1, shown in Italics, has the higher median 
DALYs lost; a (2) indicates that WHO region 2, shown in Bold, has the higher median 
DALYs lost). 
 
5. Discussion 
 
The results of the one-way ANOVA conducted on lifetime prevalence data show that 
in general, the lifetime prevalence of schizophrenia does not differ significantly across 
regions. This result supports the hypothesis that lifetime prevalence does not differ among 
WHO regions. It also supports previous research in the area, which stated that lifetime 
prevalence does not differ across regions (Jablensky, 2000).  
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There has so far been very little literature which suggests that lifetime prevalence of 
schizophrenia differs across regions. Prevalence is affected by the causes of schizophrenia 
(mentioned in Section 1), many of which are not related to country or culture, for example: 
genetic links (Nicodemus et al., 2008; Lewis et al., 2003; Badner & Gershon, 2002), 
biological sex, comorbidity with drug abuse disorders (Volkow, 2009), and stress. However, 
there are a few causes which appear to relate heavily to country and culture, including: viral 
infections such as influenza during pregnancy (Watson et al., 1999), low birth weight, hypoxia 
during birth (Nicodemus et al., 2008), and migration across countries in a person’s or their 
ancestor’s life (Cantor-Graae & Selten, 2005). Future research could potentially study 
countries and cultures which differ significantly in these factors to determine if there is a 
higher lifetime prevalence in places with more viral infections, lower birth weight, lower 
oxygen levels, and more migration. For now, the results of this study indicate that potentially 
these country- and culture-based causes have less of an effect than those causes not tied to 
country or culture. 
There were two main categories of limitations to this study: limitations of the actual 
data itself, and limitations of how this study was conducted. Firstly, I will concentrate on the 
limitations of the research. There were 79 different lifetime prevalence statistics found across 
several different studies. Each of these studies gathered their data in different ways, such as 
using self-report data, surveys, census data, etc. Also, each study conducted their research on 
different populations within their country, such as the general population, populations in 
hospitals or institutions, etc. If the data came from an especially specific population then I 
tried to exclude that data, but often the researchers did not specify. Finally, the studies were 
conducted in different years, and within that the data found was also gathered in different 
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years. All of these factors could have contributed to a biased sample of lifetime prevalence 
data. There are also limitations to how this study was conducted. As this was a meta-analysis 
senior thesis conducted by one person in a time span of four months, there were not enough 
time, resources, or people to be able to thoroughly search for lifetime prevalence data. Though 
I tried my best to be as thorough as possible, I may have missed some data due to these 
reasons, potentially creating a biased sample. In future research, I would like to conduct the 
same study on lifetime prevalence with more time and resources. 
There were huge gaps in the research on lifetime prevalence of schizophrenia across 
countries. With a more comprehensive set of data, I might have found different results. In the 
future, more research should be concentrated on those regions and specific countries which 
had no lifetime prevalence data thus far. In particular, this research should focus on the 
African Region, South-East Asia Region, and Eastern Mediterranean Region, for which I 
found two, four, and zero statistics respectively. A full table of which WHO regions and 
specific countries I found lifetime prevalence data for can be found in Appendices (Appendix 
A). 
The Kruskal-Wallis test was used in lieu of a ANOVA when analysing DALYs lost, 
because when using the latter, Levene’s p < 0.05. The results of the Kruskal-Wallis statistical 
test on DALYs lost show that there are significant differences among WHO regions. These 
results support the hypothesis that DALYs lost, and therefore prognosis, differ among regions. 
Post-hoc tests with a Bonferroni correction showed exactly which regions are different from 
each other (Table 1). There is no clear pattern of how the regions were divided. Although the 
results support my hypothesis, they did not support my predictions that  the African Region, 
South-East Asia Region, and Eastern Mediterranean Region will generally have a better 
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prognosis than the Region of the Americas, European Region, and Western Pacific Region. 
However, there were some notable conclusions to be drawn from the data: The South-East 
Asia Region, Western Pacific Region, Eastern Mediterranean Region, and Region of Americas 
were all clustered together. Each of them was similar to the others in the cluster. All differed 
significantly from the European Region. The South-East Asia Region, Western Pacific 
Region, and Eastern Mediterranean Region were all significantly different than the African 
Region - only the Region of the Americas was similar to the African Region. The European 
Region was significantly different from every region, aside from the African Region. The 
African Region was less extremely separated from the other regions than the European 
Region, being significantly different from three regions: the South-East Asia Region, Eastern 
Mediterranean Region, and Western Pacific Region. It was similar only to the European 
Region, and the Region of the Americas. The WHO regions, ordered from highest median 
DALYs lost to lowest, are listed here: Western Pacific Region, Eastern Mediterranean Region, 
South-East Asia Region, Region of the Americas, African Region, and European Region. 
There are several reasons for the general difference among WHO regions which I 
have detailed before (in Section 2.3): cultural differences in support systems, cultural stigma 
against mental illness, length of time a person spends without diagnosis and treatment, and 
economic development of a country. Although the results of the post-hoc test do not support 
my specific predictions, I do still think these cultural factors have a huge influence on the 
prognosis of people with schizophrenia. Perhaps the wide variety of cultures within the WHO 
regions had more of an effect than anticipated, causing the regions to cluster together in ways I 
did not predict. More research should be conducted to understand why the WHO regions 
cluster in the ways detailed above. 
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Since I have shown the research in these areas already, this section will focus more 
on why these factors influence prognosis. Firstly, research has shown that support and 
community are very important factors in prognosis (Elsheshtawy & Elez, 2011). Since 
schizophrenia is a disorder categorised by social isolation and stereotyped as dangerous, 
perhaps increasing support can lessen some isolation and detachment symptoms and provide 
the resources necessary to cope with daily life. Perhaps different countries and cultures within 
regions vary more than among regions. Secondly, previous literature has shown that stigma 
against mental illnesses can lead to poorer prognoses (Mascayano et al., 2016). Stigma can 
lead to systemic negligence of treatment of schizophrenia, and ostracisation of people with the 
disorder. This can lessen social support and treatment, leading to a worse prognosis. More 
research should be done within specific countries to see how stigmatised mental illness is. 
Thirdly, research has found that the longer a period of time that a person spends undiagnosed, 
the worse the prognosis for that person (Banerjee, 2012). This could be because the person 
spends longer without treatment. It also could be because the social isolation symptom of 
schizophrenia causes people to have a smaller social support system, and once again, maybe 
different countries and cultures within regions vary more than among regions. Fourthly, 
research has shown that people with schizophrenia in developing countries have better 
prognosis than people in developed countries. There is a difference of 40% recovery in 
developing countries to 25% recovery in developed countries (Torrey, 1988). I hypothesise 
that this could be due to developing countries having more social support and community, 
which has previously been shown to be linked to better prognosis. Once again, this may differ 
among countries within regions. Future research should concentrate on these factors, 
particularly social support (which seems to be a common theme in every factor), and exactly 
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how and why they influence schizophrenia within specific countries - especially those with 
little to no research thus far. This information could be used to improve the prognosis of 
people living with schizophrenia everywhere. 
There were limitations to this part of the study also. DALYs lost were measured all in 
one year by WHO. Thus far no other organisations or studies have attempted to update this 
research, or just generally gather more statistics. The fact that the data were calculated by one 
organisation in one time period could mean that the data are biased. More research should be 
done on DALYs lost across regions. Additionally, future research should concentrate on other 
ways to quantify prognosis, rather than just DALYs. 
One argument that has been used in the past to explain why prognosis of people with 
schizophrenia differs across regions is that prevalences also differ across regions. In short, if 
different regions have different prevalences, then it surely follows that they will have different 
prognoses also. However, the results of this study show that lifetime prevalence is constant 
across regions, but prognosis still differs. This finding cannot speak for other types of 
prevalence, but other literature does imply that all types of prevalence remain constant across 
countries (Bhugra, 2005). 
This study was advantageous in several ways. It is a recent meta-analysis, which are 
rare for this topic, and it gathered data on both prevalence and prognosis, which few recent 
studies do. In addition, it relates prevalence and prognosis data and explains the implications 
of having prevalence be constant across regions whilst prognosis is not. Furthermore, I strived 
to be as unbiased as possible in seeking out data for prevalence and prognosis, despite the data 
itself being biased. 
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Research on the lifetime prevalence and prognosis of schizophrenia would greatly 
benefit from more cross-cultural research. Future research should specifically concentrate on 
gathering more lifetime prevalence statistics from under-represented countries and regions and 
on further understanding why the prevalence does not differ across countries. Future research 
should also concentrate on understanding why prognosis differs across regions, and finding 
more ways to quantify prognosis. One way to do this is getting more data on specific 
countries, and finding out how they fare in the four regional factors mentioned previously. A 
very important application of this future research in prognosis is creating new treatment 
regimens based on facets of those regions and countries which have better prognosis (though 
much more thorough research is required before this becomes a feasible goal). As mentioned 
before, historical treatments of schizophrenia have been proven to be ineffective, and 
improving treatments for schizophrenia should be a central goal of future research.  
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8. Appendices 
 
Appendix A 
Table 2. A summary of all the data on lifetime prevalence that could be found, organised by 
WHO region. 
WHO Region (Country) Lifetime Prevalence Author, Year 
African (Ethiopia) 4.70 Kebede et al., 2003 
African (General Sub-Saharan) 8.00 Baingana & Bos, 2006 
Americas (Canada) 0.30 Warner & de Girolamo, 1995 
Americas (USA) 2.90 Warner & de Girolamo, 1995 
Americas (USA) 2.00 Warner & de Girolamo, 1995 
Americas (Canada) 2.10 Warner & de Girolamo, 1995 
Americas (Canada) 0.55 Ayuso-Mateos, 2006 
Americas (USA) 0.70 Ayuso-Mateos, 2006 
Americas (Chile) 0.95 Ayuso-Mateos, 2006 
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Americas (Canada) 0.60 Noaghiul & Hibbeln, 2003 
Americas (USA) 1.30 Noaghiul & Hibbeln, 2003 
South-East Asia (India) 3.70 Warner & de Girolamo, 1995 
South-East Asia (India) 0.03 Elnagar, Maitra, & Rao, 1971 
South-East Asia (Thailand) 8.80 Phanthunane et al., 2010 
South-East Asia (India) 3.70 Eaton, 1985 
European (Denmark) 3.30 Warner & de Girolamo, 1995 
European (Denmark) 8.20 Warner & de Girolamo, 1995 
European (Denmark) 2.70 Warner & de Girolamo, 1995 
European (Finland) 4.30 Warner & de Girolamo, 1995 
European (Germany) 2.40 Warner & de Girolamo, 1995 
European (Germany) 2.20 Warner & de Girolamo, 1995 
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European (Germany) 2.30 Warner & de Girolamo, 1995 
European (Iceland) 6.00 Warner & de Girolamo, 1995 
European (Iceland) 0.40 Warner & de Girolamo, 1995 
European (Norway) 5.60 Warner & de Girolamo, 1995 
European (Sweden) 9.40 Warner & de Girolamo, 1995 
European (Sweden) 5.10 Warner & de Girolamo, 1995 
European (Sweden) 5.00 Warner & de Girolamo, 1995 
European (Sweden) 0.70 Warner & de Girolamo, 1995 
European (Scotland) 4.20 Warner & de Girolamo, 1995 
European (Russia) 5.30 Warner & de Girolamo, 1995 
European (Netherlands) 0.35 Ayuso-Mateos, 2006 
European (Iceland) 0.35 Ayuso-Mateos, 2006 
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European (Israel) 0.75 Ayuso-Mateos, 2006 
European (Italy) 5.20 de Salvia et al., 1993 
European (Denmark) 2.70 Eaton, 1985 
European(Spain) 1.70 Noaghiul & Hibbeln, 2003 
European (Greece) 0.20 Noaghiul & Hibbeln, 2003 
European (Iceland) 0.30 Noaghiul & Hibbeln, 2003 
European (UK) 0.40 Noaghiul & Hibbeln, 2003 
European (Germany) 0.60 Noaghiul & Hibbeln, 2003 
European (Israel) 0.70 Noaghiul & Hibbeln, 2003 
Western Pacific (Japan) 3.80 Warner & de Girolamo, 1995 
Western Pacific (Japan) 3.20 Warner & de Girolamo, 1995 
Western Pacific (Japan) 4.10 Warner & de Girolamo, 1995 
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Western Pacific (Japan) 2.20 Warner & de Girolamo, 1995 
Western Pacific (Japan) 2.10 Warner & de Girolamo, 1995 
Western Pacific (Japan) 2.40 Warner & de Girolamo, 1995 
Western Pacific (Japan) 7.40 Warner & de Girolamo, 1995 
Western Pacific (Japan) 11.20 Warner & de Girolamo, 1995 
Western Pacific (Japan) 2.80 Warner & de Girolamo, 1995 
Western Pacific (Japan) 5.00 Warner & de Girolamo, 1995 
Western Pacific (Japan) 4.70 Warner & de Girolamo, 1995 
Western Pacific (Japan) 8.80 Warner & de Girolamo, 1995 
Western Pacific (Japan) 4.70 Warner & de Girolamo, 1995 
Western Pacific (Japan) 8.50 Warner & de Girolamo, 1995 
Western Pacific (Japan) 1.90 Warner & de Girolamo, 1995 
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Western Pacific (Japan) 17.90 Warner & de Girolamo, 1995 
Western Pacific (China) 5.70 Warner & de Girolamo, 1995 
Western Pacific (Taiwan) 3.10 Warner & de Girolamo, 1995 
Western Pacific (Taiwan) 0.90 Warner & de Girolamo, 1995 
Western Pacific (Taiwan) 2.00 Warner & de Girolamo, 1995 
Western Pacific (Taiwan) 2.50 Warner & de Girolamo, 1995 
Western Pacific (Hong Kong) 1.25 Chang et al., 2017 
Western Pacific (Taiwan) 0.30 Ayuso-Mateos, 2006 
Western Pacific (China) 0.55 Ayuso-Mateos, 2006 
Western Pacific (China) 0.49 Xiang et al., 2008 
Western Pacific (China) 0.39 Chan et al., 2015 
Western Pacific (China) 0.57 Chan et al., 2015 
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Western Pacific (China) 0.83 Chan et al., 2015 
Western Pacific (South Korea) 0.35 Ayuso-Mateos, 2006 
Western Pacific (Hong Kong) 1.25 Ayuso-Mateos, 2006 
Western Pacific (New Zealand) 0.35 Ayuso-Mateos, 2006 
Western Pacific (Taiwan) 1.40 Eaton, 1985 
Western Pacific (Taiwan) 0.90 Eaton, 1985 
Western Pacific (Hong Kong) 0.10 Noaghiul & Hibbeln, 2003 
Western Pacific (Taiwan) 0.30 Noaghiul & Hibbeln, 2003 
Western Pacific (New Zealand) 0.30 Noaghiul & Hibbeln, 2003 
Western Pacific (Australia) 0.50 Noaghiul & Hibbeln, 2003 
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Appendix B 
 
Table 3. Factors that influence schizophrenia which are not necessarily related to cultural 
differences (Torrey, 1988). 
Factor Affecting Prognosis Good Prognosis Poor Prognosis 
Age of onset Younger Older 
Gender Female Male 
Family history of mental 
illness, including schizophrenia 
No mental illness (except 
depression or manic-depressive 
psychosis) 
History of mental illness is 
present 
Suddenness of onset Sudden Gradual 
Number of stressful life events Several Few 
Symptom types Positive symptoms Negative symptoms 
Initial response to medications Good Poor 
Independence Ability to function in society Difficulty living outside of 
structured institutions 
 
